SeeThruEquity Issues Update on BioSig Technologies, Inc. (OTCQB: BSGM)
NEW YORK, NY / ACCESSWIRE / January 19, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on BioSig Technologies, Inc. (BSGM).
The report is available here: BSGM January 2017 Update Note.
BioSig appears to be positioned for a watershed 2017. PURE EP appears to be establishing itself as a promising new tool for arrhythmia treatments, market, with favorable peer reviews and scientific collaborations at prestigious institutions including the Mayo Clinic and Mount Sinai, and UCLA, among others.
Additional highlights from the update include the following:
Expect 2017 to be pivotal year for BioSig
We see several catalysts on the horizon for BioSig in 2017. The company appears to have been garnering attention in its field with a favorable presence in well-regarded peer reviewed journals as it approaches commercialization for its flagship PURE EP™ System. The PURE EP™ System is designed to improve the process of identifying catheter ablation targets - areas of tissue to destroy that otherwise create a cardiac arrhythmia. On the regulatory front, BioSig is advancing toward a 510(k) FDA clearance pathway for the PURE EP™ System, which management expects to be complete during this calendar year (2017). If accomplished, we would see this as a major milestone for an emerging company with what appears to be a differentiated, innovative device in an industry segment that has been marked by consolidation.
PURE EP attracts attention in scientific community with PURE EP featured in leading peer-reviewed publication JACC
On January 11, 2017, BioSig announced that the PURE EP System, was featured in The Journal of the American College of Cardiology (JACC): Clinical Electrophysiology, a leading peer-reviewed publication focused on care and heart health in the area of cardiac electrophysiology. The article was called Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals, and was completed by Dr. Samuel Asirvatham, Vice Chair of Cardiovascular Diseases and Program Director of Clinical Cardiac Electrophysiology Training Program at the Mayo Clinic in Rochester, MN, and his team. Dr. Asirvatham's study highlighted potential benefits of PURE EP versus standard recording systems, particularly using the PURE EP during catheter ablation for improved analysis of signals in the heart's lower ventricles, possibly improving treatment for these types of complex arrhythmias.
BSGM aiming for FDA clearance in 2017
BSGM is targeting FDA clearance for the PURE EP System by the end of 2017, via a 510(k) pathway. We would view this as a major accomplishment by management, and a potential valuation catalyst. The PURE EP appears to be establishing itself as a promising new tool for arrhythmia treatments, market, with favorable peer reviews and scientific collaborations at prestigious institutions including the Mayo Clinic and Mount Sinai, and UCLA, among others.
Please review important disclosures at www.seethruequity.com.
About BioSig Technologies, Inc.
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $3 billion electrophysiology (EP) marketplace1 (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the EPs in identifying ablation targets -- areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 20191 -- making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 20172.
BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through UCLA labs, and has performed pre-clinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.
About SeeThruEquity
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.
SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry-s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
info@seethruequity.com
SOURCE: SeeThruEquity
